Abstract
Another session of KRC RAMS began with a Russian-French symposium devoted to the use of the new -blocker lokren (betaxololol) in the treatment of arterial hypertension (AH). As the chairman of the symposium prof. Y.N. Belenkov (Moscow) noted, the continuing interest to the search of new tools for AH treatment is caused primarily by the fact that our country annually loses over 500 thousand people from AH and its complications. The available arsenal of hypotensive drugs is thoroughly reconsidered from the position of modern views on the pathogenesis of AH and the influence of these drugs on the quality of life.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
